$7.70 Million in Sales Expected for Intellia Therapeutics Inc (NTLA) This Quarter

Equities research analysts forecast that Intellia Therapeutics Inc (NASDAQ:NTLA) will report sales of $7.70 million for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Intellia Therapeutics’ earnings, with the highest sales estimate coming in at $10.63 million and the lowest estimate coming in at $5.00 million. Intellia Therapeutics reported sales of $7.68 million during the same quarter last year, which would suggest a positive year over year growth rate of 0.3%. The business is scheduled to report its next quarterly earnings results on Wednesday, August 7th.

According to Zacks, analysts expect that Intellia Therapeutics will report full year sales of $28.82 million for the current financial year, with estimates ranging from $10.40 million to $42.50 million. For the next year, analysts forecast that the firm will report sales of $31.48 million, with estimates ranging from $20.00 million to $44.40 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Intellia Therapeutics.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, May 2nd. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.04. The firm had revenue of $10.43 million during the quarter, compared to analyst estimates of $9.43 million. Intellia Therapeutics had a negative net margin of 257.28% and a negative return on equity of 31.68%. Intellia Therapeutics’s revenue was up 39.7% on a year-over-year basis. During the same period in the previous year, the business posted ($0.51) EPS.

A number of research analysts recently commented on the company. BidaskClub raised Intellia Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, April 5th. Zacks Investment Research downgraded Intellia Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 7th. Evercore ISI assumed coverage on Intellia Therapeutics in a research note on Thursday, April 11th. They issued an “outperform” rating for the company. Chardan Capital reaffirmed a “buy” rating and issued a $57.50 price target on shares of Intellia Therapeutics in a research note on Wednesday, February 27th. Finally, Wedbush raised Intellia Therapeutics from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $20.00 to $21.00 in a research note on Friday, May 3rd. One analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $29.25.

In related news, EVP Andrew Schiermeier purchased 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The stock was acquired at an average price of $15.72 per share, with a total value of $117,900.00. Following the completion of the purchase, the executive vice president now directly owns 3,250 shares in the company, valued at $51,090. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.10% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. We Are One Seven LLC bought a new stake in Intellia Therapeutics in the fourth quarter worth approximately $28,000. Tortoise Investment Management LLC grew its stake in shares of Intellia Therapeutics by 100.0% in the first quarter. Tortoise Investment Management LLC now owns 2,000 shares of the company’s stock valued at $34,000 after buying an additional 1,000 shares in the last quarter. Quantamental Technologies LLC grew its stake in shares of Intellia Therapeutics by 1,170.4% in the first quarter. Quantamental Technologies LLC now owns 3,303 shares of the company’s stock valued at $56,000 after buying an additional 3,043 shares in the last quarter. Patriot Financial Group Insurance Agency LLC grew its stake in shares of Intellia Therapeutics by 35.8% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 5,495 shares of the company’s stock valued at $75,000 after buying an additional 1,450 shares in the last quarter. Finally, Nikko Asset Management Americas Inc. grew its stake in shares of Intellia Therapeutics by 20.0% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 5,980 shares of the company’s stock valued at $82,000 after buying an additional 995 shares in the last quarter. 71.33% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics stock traded up $0.38 during midday trading on Friday, reaching $15.88. 273,423 shares of the stock traded hands, compared to its average volume of 588,386. The company has a quick ratio of 7.74, a current ratio of 7.74 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $683.84 million, a price-to-earnings ratio of -7.91 and a beta of 2.79. Intellia Therapeutics has a fifty-two week low of $11.03 and a fifty-two week high of $32.95.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.

Featured Story: How prevalent are 12b-1 fees?

Get a free copy of the Zacks research report on Intellia Therapeutics (NTLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.